{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T13:35:17Z","timestamp":1792157717069,"version":"4.4.0"},"reference-count":64,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","euoncology.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Oncology"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.euo.2026.06.012","type":"journal-article","created":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T19:39:23Z","timestamp":1783539563000},"page":"986-996","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Molecular Profiling of Urothelial Bladder Cancer: Bridging Tumor Biology and Clinical Decision-making"],"prefix":"10.1016","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9082-1341","authenticated-orcid":false,"given":"Constance","family":"Thibault","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9l\u00e8ne","family":"Blons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yves","family":"Allory","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alia","family":"Harba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathieu","family":"Roumigui\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Seisen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gautier","family":"Marcq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Sophie","family":"Bajeot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priscilla","family":"Leon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Masson-Lecomte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Prad\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evanguelos","family":"Xylinas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doriane","family":"Prost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-Etienne","family":"Gabriel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Laurent-Puig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgan","family":"Roupr\u00eat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francois","family":"Audenet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euo.2026.06.012_b0005","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.euo.2026.06.012_b0010","article-title":"Identification of prognostic biomarkers for bladder cancer based on DNA methylation profile","volume":"9","author":"Zhang","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.euo.2026.06.012_b0015","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.eururo.2020.12.033","article-title":"European Association of Urology (EAU) prognostic factor risk groups for non-muscle-invasive bladder cancer (NMIBC) incorporating the WHO 2004\/2016 and WHO 1973 classification systems for grade: an update from the EAU NMIBC guidelines panel","volume":"79","author":"Sylvester","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2026.06.012_b0020","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S0002-9440(10)65318-7","article-title":"Frequent genetic alterations in simple urothelial hyperplasias of the bladder in patients with papillary urothelial carcinoma","volume":"154","author":"Hartmann","year":"1999","journal-title":"Am J Pathol"},{"key":"10.1016\/j.euo.2026.06.012_b0025","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/nrc3817","article-title":"Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity","volume":"15","author":"Knowles","year":"2015","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.euo.2026.06.012_b0030","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1038\/s41467-021-22465-w","article-title":"An integrated multi-omics analysis identifies prognostic molecular subtypes of non-muscle-invasive bladder cancer","volume":"12","author":"Lindskrog","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.euo.2026.06.012_b0035","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.eururo.2013.08.052","article-title":"Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome","volume":"65","author":"Allory","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2026.06.012_b0040","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s13073-022-01056-4","article-title":"Combined exome and transcriptome sequencing of non-muscle-invasive bladder cancer: associations between genomic changes, expression subtypes, and clinical outcomes","volume":"14","author":"Goel","year":"2022","journal-title":"Genome Med"},{"key":"10.1016\/j.euo.2026.06.012_b0045","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.ccell.2017.08.005","article-title":"Genomic subtypes of non-invasive bladder cancer with distinct metabolic profile and female gender bias in KDM6A mutation frequency","volume":"32","author":"Hurst","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.euo.2026.06.012_b0050","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.eururo.2017.05.032","article-title":"Next-generation sequencing of nonmuscle invasive bladder cancer reveals potential biomarkers and rational therapeutic targets","volume":"72","author":"Pietzak","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2026.06.012_b0055","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.cell.2017.09.007","article-title":"Comprehensive molecular characterization of muscle-invasive bladder cancer","volume":"171","author":"Robertson","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.euo.2026.06.012_b0060","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1158\/1078-0432.CCR-18-3147","article-title":"Mutational analysis of 472 urothelial carcinoma across grades and anatomic sites","volume":"25","author":"Nassar","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.euo.2026.06.012_b0065","doi-asserted-by":"crossref","first-page":"3664","DOI":"10.1200\/JCO.2005.05.1771","article-title":"Prospective study of FGFR3 mutations as a prognostic factor in nonmuscle invasive urothelial bladder carcinomas","volume":"24","author":"Hern\u00e1ndez","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2026.06.012_b0070","doi-asserted-by":"crossref","first-page":"6008","DOI":"10.1158\/1078-0432.CCR-09-0898","article-title":"Spectrum of phosphatidylinositol 3-kinase pathway gene alterations in bladder cancer","volume":"15","author":"Platt","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.euo.2026.06.012_b0075","doi-asserted-by":"crossref","first-page":"7401","DOI":"10.1158\/0008-5472.CAN-06-1182","article-title":"PIK3CA mutations are an early genetic alteration associated with FGFR3 mutations in superficial papillary bladder tumors","volume":"66","author":"L\u00f3pez-Knowles","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.euo.2026.06.012_b0080","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/s41588-024-02030-z","article-title":"Comprehensive genomic characterization of early-stage bladder cancer","volume":"57","author":"Prip","year":"2025","journal-title":"Nat Genet"},{"key":"10.1016\/j.euo.2026.06.012_b0085","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ccell.2016.05.004","article-title":"Comprehensive transcriptional analysis of early-stage urothelial carcinoma","volume":"30","author":"Hedegaard","year":"2016","journal-title":"Cancer Cell"},{"key":"10.1016\/j.euo.2026.06.012_b0090","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.eururo.2018.09.002","article-title":"Genomic differences between \u201cprimary\u201d and \u201csecondary\u201d muscle-invasive bladder cancer as a basis for disparate outcomes to cisplatin-based neoadjuvant chemotherapy","volume":"75","author":"Pietzak","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2026.06.012_b0095","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.eururo.2020.06.048","article-title":"Identification of differential tumor subtypes of T1 bladder cancer","volume":"78","author":"Robertson","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2026.06.012_b0100","article-title":"Stage-stratified molecular profiling of non-muscle-invasive bladder cancer enhances biological, clinical, and therapeutic insight","volume":"2","author":"Hurst","year":"2021","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.euo.2026.06.012_b0105","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abn4118","article-title":"Non-muscle-invasive bladder cancer molecular subtypes predict differential response to intravesical Bacillus Calmette-Gu\u00e9rin","volume":"15","author":"de Jong","year":"2023","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.euo.2026.06.012_b0110","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/nrm3838","article-title":"Regulation of microRNA biogenesis","volume":"15","author":"Ha","year":"2014","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.euo.2026.06.012_b0115","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.cell.2009.01.002","article-title":"MicroRNAs: target recognition and regulatory functions","volume":"136","author":"Bartel","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.euo.2026.06.012_b0120","doi-asserted-by":"crossref","first-page":"42258","DOI":"10.18632\/oncotarget.5546","article-title":"A Polycomb-mir200 loop regulates clinical outcome in bladder cancer","volume":"6","author":"Mart\u00ednez-Fern\u00e1ndez","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.euo.2026.06.012_b0125","doi-asserted-by":"crossref","first-page":"16043","DOI":"10.18632\/oncotarget.3755","article-title":"MicroRNA-155 promotes bladder cancer growth by repressing the tumor suppressor DMTF1","volume":"6","author":"Peng","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.euo.2026.06.012_b0130","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s40164-025-00649-0","article-title":"Validation of a microRNA profile in urine liquid biopsy with diagnostic and stratification value for bladder cancer classification, available through the open app BladdermiRaCan","volume":"14","author":"Oto","year":"2025","journal-title":"Exp Hematol Oncol"},{"key":"10.1016\/j.euo.2026.06.012_b0135","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/s41576-018-0074-2","article-title":"Clinical epigenetics: seizing opportunities for translation","volume":"20","author":"Berdasco","year":"2019","journal-title":"Nat Rev Genet"},{"key":"10.1016\/j.euo.2026.06.012_b0140","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.euf.2024.05.024","article-title":"Diagnostic test accuracy of urinary DNA methylation-based biomarkers for the detection of primary and recurrent bladder cancer: a systematic review and meta-analysis","volume":"10","author":"Silva-Ferreira","year":"2024","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.euo.2026.06.012_b0145","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s13148-016-0303-5","article-title":"UroMark-a urinary biomarker assay for the detection of bladder cancer","volume":"9","author":"Feber","year":"2017","journal-title":"Clin Epigenet"},{"key":"10.1016\/j.euo.2026.06.012_b0150","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.eururo.2025.02.011","article-title":"Towards epigenetic-based subtyping of bladder cancer: DNA methylation predicts molecular subtypes of non-muscle-invasive bladder cancer","volume":"87","author":"Yu","year":"2025","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2026.06.012_b0155","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/nature12965","article-title":"Comprehensive molecular characterization of urothelial bladder carcinoma","volume":"507","author":"Cancer Genome Atlas Research Network","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.euo.2026.06.012_b0160","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1200\/JCO.23.01983","article-title":"NECTIN4 amplification is frequent in solid tumors and predicts enfortumab vedotin response in metastatic urothelial cancer","volume":"42","author":"Kl\u00fcmper","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2026.06.012_b0165","doi-asserted-by":"crossref","first-page":"17426","DOI":"10.1073\/pnas.1310522110","article-title":"TERT promoter mutations in bladder cancer affect patient survival and disease recurrence through modification by a common polymorphism","volume":"110","author":"Rachakonda","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.euo.2026.06.012_b0170","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1158\/1078-0432.CCR-13-1992","article-title":"A high frequency of activating extracellular domain ERBB2 (HER2) mutation in micropapillary urothelial carcinoma","volume":"20","author":"Ross","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.euo.2026.06.012_b0175","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.eururo.2016.02.056","article-title":"Gene expression profile of the clinically aggressive micropapillary variant of bladder cancer","volume":"70","author":"Guo","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2026.06.012_b0180","doi-asserted-by":"crossref","first-page":"3110","DOI":"10.1073\/pnas.1318376111","article-title":"Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology","volume":"111","author":"Damrauer","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.euo.2026.06.012_b0185","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3008970","article-title":"EGFR as a potential therapeutic target for a subset of muscle-invasive bladder cancers presenting a basal-like phenotype","volume":"6","author":"Rebouissou","year":"2014","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.euo.2026.06.012_b0190","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ccr.2014.01.009","article-title":"Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy","volume":"25","author":"Choi","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.euo.2026.06.012_b0195","doi-asserted-by":"crossref","first-page":"3737","DOI":"10.1038\/s41598-018-22126-x","article-title":"A validation and extended description of the Lund taxonomy for urothelial carcinoma using the TCGA cohort","volume":"8","author":"Marzouka","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.euo.2026.06.012_b0200","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1093\/jnci\/djx243","article-title":"Prognostic power of a tumor differentiation gene signature for bladder urothelial carcinomas","volume":"110","author":"Mo","year":"2018","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.euo.2026.06.012_b0205","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.eururo.2019.09.006","article-title":"A consensus molecular classification of muscle-invasive bladder cancer","volume":"77","author":"Kamoun","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2026.06.012_b0210","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.annonc.2024.09.008","article-title":"Basal\/squamous and mixed subtype bladder cancers present poor outcomes after neoadjuvant chemotherapy in the VESPER trial","volume":"36","author":"Groeneveld","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.euo.2026.06.012_b0215","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1002\/path.6062","article-title":"The Lund taxonomy for bladder cancer classification - from gene expression clustering to cancer cell molecular phenotypes, and back again","volume":"259","author":"H\u00f6glund","year":"2023","journal-title":"J Pathol"},{"key":"10.1016\/j.euo.2026.06.012_b0220","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1186\/s12967-025-06682-1","article-title":"Pathway-based cancer transcriptome deciphers a high-resolution intrinsic heterogeneity within bladder cancer classification","volume":"23","author":"Wang","year":"2025","journal-title":"J Transl Med"},{"key":"10.1016\/j.euo.2026.06.012_b0225","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1002\/ijc.34715","article-title":"Metastasis and recurrence patterns in the molecular subtypes of urothelial bladder cancer","volume":"154","author":"Sj\u00f6dahl","year":"2024","journal-title":"Int J Cancer"},{"key":"10.1016\/j.euo.2026.06.012_b0230","doi-asserted-by":"crossref","unstructured":"Wang Z, He W, Wang M, et al. Integrated multicenter single-cell atlas of bladder cancer reveals tumor heterogeneity associated with immunotherapy. Int J Surg. In press. https:\/\/doi.org\/10.1097\/JS9.0000000000003830.","DOI":"10.1097\/JS9.0000000000003830"},{"key":"10.1016\/j.euo.2026.06.012_b0235","doi-asserted-by":"crossref","first-page":"4858","DOI":"10.1038\/s41467-020-18640-0","article-title":"Molecular correlates of cisplatin-based chemotherapy response in muscle invasive bladder cancer by integrated multi-omics analysis","volume":"11","author":"Taber","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.euo.2026.06.012_b0240","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.eururo.2015.07.009","article-title":"Defects in DNA repair genes predict response to neoadjuvant cisplatin-based chemotherapy in muscle-invasive bladder cancer","volume":"68","author":"Plimack","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2026.06.012_b0245","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1001\/jamaoncol.2016.1056","article-title":"Clinical validation of chemotherapy response biomarker ERCC2 in muscle-invasive urothelial bladder carcinoma","volume":"2","author":"Liu","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.euo.2026.06.012_b0250","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.annonc.2025.09.139","article-title":"Adjuvant nivolumab versus placebo for high-risk muscle-invasive urothelial carcinoma: 5-year efficacy and ctDNA results from CheckMate 274","volume":"37","author":"Galsky","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.euo.2026.06.012_b0255","doi-asserted-by":"crossref","first-page":"4503","DOI":"10.1200\/JCO.2025.43.16_suppl.4503","article-title":"Circulating tumor DNA (ctDNA) in patients with muscle-invasive bladder cancer (MIBC) who received perioperative durvalumab (D) in Niagara","volume":"43","author":"Powles","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2026.06.012_b0260","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1056\/NEJMoa2511885","article-title":"ctDNA-guided adjuvant atezolizumab in muscle-invasive bladder cancer","volume":"393","author":"Powles","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2026.06.012_b0265","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1038\/s41467-023-37568-9","article-title":"Expression-based subtypes define pathologic response to neoadjuvant immune-checkpoint inhibitors in muscle-invasive bladder cancer","volume":"14","author":"Robertson","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.euo.2026.06.012_b0270","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.1200\/JCO.22.02144","article-title":"Novel genetic subtypes of urothelial carcinoma with differential outcomes on immune checkpoint blockade","volume":"41","author":"Sarfaty","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2026.06.012_b0275","doi-asserted-by":"crossref","first-page":"8603","DOI":"10.1038\/s41467-024-52915-0","article-title":"The genomic and transcriptomic landscape of metastastic urothelial cancer","volume":"15","author":"Loriot","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.euo.2026.06.012_b0280","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1002\/cncr.29826","article-title":"Comprehensive genomic profiling of 295 cases of clinically advanced urothelial carcinoma of the urinary bladder reveals a high frequency of clinically relevant genomic alterations","volume":"122","author":"Ross","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.euo.2026.06.012_b0285","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.eururo.2022.01.026","article-title":"Comprehensive molecular characterization reveals genomic and transcriptomic subtypes of metastatic urothelial carcinoma","volume":"81","author":"Nakauma-Gonz\u00e1lez","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2026.06.012_b0290","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1093\/annonc\/mdw170","article-title":"Tumor heterogeneity of fibroblast growth factor receptor 3 (FGFR3) mutations in invasive bladder cancer: implications for perioperative anti-FGFR3 treatment","volume":"27","author":"Pouessel","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.euo.2026.06.012_b0295","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1056\/NEJMoa2308849","article-title":"Erdafitinib or chemotherapy in advanced or metastatic urothelial carcinoma","volume":"389","author":"Loriot","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2026.06.012_b0300","doi-asserted-by":"crossref","first-page":"S1137","DOI":"10.1016\/j.annonc.2024.08.2051","article-title":"1966MO EV-302: exploratory analysis of nectin-4 expression and response to 1L enfortumab vedotin (EV) + pembrolizumab (P) in previously untreated locally advanced or metastatic urothelial cancer (la\/mUC)","volume":"35","author":"Powles","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.euo.2026.06.012_b0305","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1111\/his.15130","article-title":"Associations of TACSTD2\/TROP2 and NECTIN-4\/NECTIN-4 with molecular subtypes, PD-L1 expression, and FGFR3 mutational status in two advanced urothelial bladder cancer cohorts","volume":"84","author":"Bahlinger","year":"2024","journal-title":"Histopathology"},{"key":"10.1016\/j.euo.2026.06.012_b0310","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s11255-014-0866-z","article-title":"Prognostic role of HER2 expression in bladder cancer: a systematic review and meta-analysis","volume":"47","author":"Zhao","year":"2015","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.euo.2026.06.012_b0315","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer","volume":"390","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2026.06.012_b0320","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 Phase II trial","volume":"42","author":"Meric-Bernstam","year":"2024","journal-title":"J Clin Oncol"}],"container-title":["European Urology Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931126001823?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931126001823?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T16:47:41Z","timestamp":1789577261000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2588931126001823"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":64,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S2588931126001823"],"URL":"https:\/\/doi.org\/10.1016\/j.euo.2026.06.012","relation":{},"ISSN":["2588-9311"],"issn-type":[{"value":"2588-9311","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Molecular Profiling of Urothelial Bladder Cancer: Bridging Tumor Biology and Clinical Decision-making","name":"articletitle","label":"Article Title"},{"value":"European Urology Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euo.2026.06.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}